BioResireNov 2

Unlock top career opportunities in Bioinformatics with BioResire!
Leading companies in Bangalore and Hyderabad are hiring skilled professionals.
Advance your future with the best industry connections and real-world guidance.
Join BioResire to start your journey toward a successful bioinformatics career!

#BioinformaticsJobs #DataScience #Genomics #LifeScienceCareers #BioinformaticsTraining #BiotechIndustry #NextGenCareers #STEMEducation #HealthcareIT #ClinicalResearch #DigitalHealth #JobSearch

Yonhap Infomax NewsMay 22, 2025
Samsung Biologics announces spin-off to separate CDMO and biosimilar businesses, aiming to resolve conflicts of interest and secure growth momentum in both sectors.
#YonhapInfomax #SamsungBiologics #CDMO #Biosimilars #CorporateRestructuring #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64326
Samsung Biologics - 'Securing Growth Momentum by Resolving CDMO-Biosimilar Conflicts'

Samsung Biologics announces spin-off to separate CDMO and biosimilar businesses, aiming to resolve conflicts of interest and secure growth momentum in both sectors.

Yonhap Infomax
Yonhap Infomax NewsMay 22, 2025
Samsung Biologics announces spin-off to create Samsung Epis Holdings, sparking market speculation about potential governance restructuring and impacting stock prices of Samsung C&T and Samsung Biologics.
#YonhapInfomax #SamsungBiologics #SpinOff #SamsungCT #GovernanceRestructuring #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64316
Samsung Bioepis' Spin-off Sparks Diverse Interpretations - Why Samsung C&T's Stock Price Reacted

Samsung Biologics announces spin-off to create Samsung Epis Holdings, sparking market speculation about potential governance restructuring and impacting stock prices of Samsung C&T and Samsung Biologics.

Yonhap Infomax
Yonhap Infomax NewsMay 22, 2025
Samsung Biologics maintains its financial outlook for the year, indicating stability in its business operations despite recent corporate restructuring
#YonhapInfomax #SamsungBiologics #FinancialGuidance #CorporateSplit #BiotechIndustry #BusinessOutlook #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64304
Samsung Biologics - 'No Major Changes to This Year's Guidance After Split'

Samsung Biologics maintains its financial outlook for the year, indicating stability in its business operations despite recent corporate restructuring

Yonhap Infomax
Yonhap Infomax NewsMay 22, 2025
Samsung Biologics clarifies it is not currently considering an initial public offering for its subsidiary Samsung Bioepis, dispelling market speculation
#YonhapInfomax #SamsungBiologics #SamsungBioepis #IPO #BiotechIndustry #CorporateStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64302
Samsung Biologics - 'Not Considering IPO for Samsung Bioepis'

Samsung Biologics clarifies it is not currently considering an initial public offering for its subsidiary Samsung Bioepis, dispelling market speculation

Yonhap Infomax
Yonhap Infomax NewsMay 21, 2025
Samsung Biologics announces corporate restructuring, splitting into two entities to enhance operational efficiency and focus on core business areas
#YonhapInfomax #SamsungBiologics #CorporateRestructuring #CompanySplit #SamsungEpisHoldings #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64251
Samsung Biologics to Split into Samsung Biologics and Samsung Epis Holdings

Samsung Biologics announces corporate restructuring, splitting into two entities to enhance operational efficiency and focus on core business areas

Yonhap Infomax
Yonhap Infomax NewsMay 21, 2025
Samsung Biologics announces strategic split, forming separate entities Samsung Biologics and Samsung Epis Holdings to enhance operational focus and market competitiveness
#YonhapInfomax #SamsungBiologics #CorporateSplit #SamsungEpisHoldings #BiotechIndustry #CorporateRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64250
Samsung Biologics to Split into Samsung Biologics and Samsung Epis Holdings

Samsung Biologics announces strategic split, forming separate entities Samsung Biologics and Samsung Epis Holdings to enhance operational focus and market competitiveness

Yonhap Infomax
Yonhap Infomax NewsMay 7, 2025
SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations amid challenging biotech landscape
#YonhapInfomax #SKBioscience #Q1Results #OperatingLoss #BiotechIndustry #FinancialPerformance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61986
SK Bioscience Q1 Operating Loss at 15.1 Billion Won - Better Than Expected

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations amid challenging biotech landscape

Yonhap Infomax
Yonhap Infomax NewsApr 7, 2025
ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
#YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=57545
ABL Bio Exports $3.4 Billion Drug Platform Technology

ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea

Yonhap Infomax
Yonhap Infomax NewsMar 10, 2025
US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism
#YonhapInfomax #TernsPharmaceuticals #ObesityDrug #GLP1 #StockForecast #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=53550
GLP-1 Obesity Drug Could Succeed... US Pharma Terns' Stock Expected to Rise 5-fold

US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism

Yonhap Infomax